Im­munother­a­py biotech un­stealths with $13M; An­ti-in­fec­tion can­di­date for CF pass­es safe­ty tri­al

Shen­non Biotech­nolo­gies has raised $13 mil­lion in seed fund­ing for a sin­gle cell plat­form to cre­ate more ef­fec­tive im­munother­a­pies. The com­pa­ny says the plat­form can “pro­file mil­lions of im­mune cells func­tion­al­ly at the sin­gle cell lev­el with­in a few hours” in or­der to iden­ti­fy TCR or an­ti­body tar­gets.

“This tech­nol­o­gy has the po­ten­tial to over­come a key bot­tle­neck in im­munother­a­py by iden­ti­fy­ing rare anti­gen-spe­cif­ic im­mune cells through en­abling high-through­put analy­sis of func­tion­al pair­ing be­tween ef­fec­tor and tar­get cells in a way that was pre­vi­ous­ly im­pos­si­ble,” Joseph Frai­et­ta, a sci­en­tif­ic ad­vi­sor for Shen­non and di­rec­tor of the Sol­id Tu­mor Im­munother­a­py Lab at the Uni­ver­si­ty of Penn­syl­va­nia, said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER